health
Simulations Plus Expands FDA Adoption of ADMET Predictor® with New Licenses for the Cosmetics Regulatory Science Branch
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that the U.S. Food and Drug Administration’s (FDA) Cosmetics Regulatory Science Branch has licensed ADMET Predictor® to support its computational research for modern cosmetic safety assessment. The contract expands the use of Simulations Plus technology
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories
Amesite Announces New Sales Win Under NurseMagic® Minimum Enterprise Pricing Model
Globenewswire_fr
aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
Globenewswire_fr
Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring
Globenewswire_fr
Adventure With a Purpose: A Race Against Blindness Unveils Adventure Package Fundraiser Valued at $350,000
Globenewswire_fr
Re: Management of paracetamol (acetaminophen) toxicity
Bmj